CALCIUM CHANNEL BLOCKER (CCB) TOXICITY

Emergency Medicine Exam Notes

1. PHARMACOLOGY - HIGH YIELD

Mechanism of Action

• CCBs bind the alpha-1 subunit of L-type calcium channels - favor the closed state, decrease calcium entry
• L-type channels found in: heart, vascular smooth muscle, pancreatic beta-islet cells
• At very high concentrations (especially verapamil): may physically occlude the channel canal

Four Key Physiologic Effects Blocked by CCBs

1. SA node depolarization (pacemaker activity)
2. AV nodal conduction
3. Myocardial contraction
4. Insulin release from pancreatic beta cells

Exam pearl: Verapamil overdose causes more deaths than ALL other CCBs combined - it is the most potent negative inotrope and causes equal depression of contraction and vascular smooth muscle dilatation simultaneously.

Drug Classes - "PINE = Dihydropyridine" Rule

Exam pearl: Dihydropyridines cause REFLEX TACHYCARDIA (not bradycardia) in overdose because they are vascular-selective - they drop BP via vasodilation, triggering compensatory tachycardia. Non-DHPs (verapamil, diltiazem) cause bradycardia + hypotension.

Metabolism

• All CCBs: hepatic via CYP3A4
• Extended-release formulations: delayed toxicity - symptoms may not appear for 6-8 hours

2. CLINICAL PRESENTATION

Classic Triad of Non-DHP Overdose

1. Bradycardia
2. Hypotension
3. Hyperglycemia (insulin release blocked)

Exam pearl: Hyperglycemia in CCB overdose is a marker of toxicity severity - it correlates with the degree of L-type channel blockade in pancreatic beta cells.

DHP Overdose

• Hypotension + reflex tachycardia (or normal HR)
• Less cardiac depression but can still be severe

ECG Changes

• Bradycardia
• PR prolongation
• High-degree AV block (2nd or 3rd degree)
• Wide complex bradycardia in severe poisoning

Symptoms by Severity

3. DIAGNOSIS

• Clinical diagnosis based on history + presentation
• ECG: bradycardia, AV conduction abnormalities
• Glucose: hyperglycemia suggests significant toxicity
• Serum drug levels: not routinely available or useful in acute management
• Consider: co-ingestion with beta-blockers (synergistic toxicity - far worse outcome)

Exam pearl: Beta-blocker + CCB co-ingestion = catastrophic synergy. Both cause bradycardia and negative inotropy via different mechanisms - treat aggressively.

4. MANAGEMENT - THE EXAM CORE

Step-by-Step Approach

Step 1: GI Decontamination

• Activated charcoal (1 g/kg): give if within 1-2 hours of ingestion and airway is protected
• Whole bowel irrigation with polyethylene glycol: for sustained-release CCB ingestions
  • Continue until rectal effluent is clear

Step 2: Atropine

• First-line for symptomatic bradycardia
• Dose: 0.5-1 mg IV (up to 3 mg total)
• Often ineffective in significant CCB overdose (vagolytic mechanism does not overcome L-type channel blockade)
• Use as a temporizing measure

Step 3: Calcium

• First-line antidote for CCB toxicity
• Mechanism: increases extracellular calcium gradient, partially overcomes channel blockade
• Two formulations:
  • Calcium chloride 10% - 3x more elemental calcium per mL (preferred for severe cases)
  • Calcium gluconate 10% - safer for peripheral IV

• Repeat every 15-20 minutes for up to 4 doses
• Can start calcium infusion if initial doses effective but effect wanes
• Monitor: ionized calcium, ECG, serum calcium (goal: 2x normal ionized calcium)
• Hypercalcemia = do not redose; toxicity without benefit
• Avoid: calcium may worsen digoxin toxicity if co-ingested

Step 4: High-Dose Insulin (HDI) - CRITICAL TO KNOW

• Most promising treatment for myocardial suppression from CCB poisoning
• Mechanism of action:
  1. Positive inotropy
  2. Increased calcium entry into cardiomyocytes
  3. Improved myocardial carbohydrate utilization (CCBs impair glucose uptake in myocardium)

Exam pearl: HDI dose is FAR higher than therapeutic insulin doses. 1 unit/kg bolus followed by infusion up to 10 units/kg/hr. Therapeutic response noted within 15-30 minutes.

Step 5: Adrenergic Agents (vasopressors)

• For patients not responding to calcium or requiring repeated calcium doses
• Goal: MAP ≥65 mmHg
• No single agent is consistently superior
• Epinephrine or norepinephrine preferred for patients with decreased contractility + vasodilation + relative bradycardia (both alpha- and beta-agonist effects)
• Other options: dopamine, vasopressin, dobutamine, isoproterenol
• Methylene blue (nitric oxide scavenger): reported benefit for vasoplegic shock
• Phosphodiesterase inhibitors (milrinone, amrinone, enoximone): case reports of benefit
• High-dose/multi-agent vasopressors acceptable when standard doses fail - risk of ischemic complications

Step 6: Glucagon

• Mechanism: bypasses L-type channel, increases cAMP directly
• Dose: 3-10 mg IV bolus, then 3-5 mg/hr infusion
• Role: adjunct when other therapies fail
• Side effects: nausea, vomiting (common - pre-treat with antiemetic)

Step 7: Lipid Emulsion Therapy (ILE)

• Mechanism: "lipid sink" - sequesters lipophilic CCB drug into plasma lipid phase
• Most evidence for lipophilic drugs (verapamil is lipophilic)
• Dose: 20% lipid emulsion 1.5 mL/kg IV bolus, then 0.25 mL/kg/min infusion
• Use for: refractory shock not responding to other measures

Step 8: Cardiac Pacing

• Transvenous or transcutaneous pacing for refractory bradycardia
• Electrical capture may occur without mechanical capture (pulseless electrical activity pattern)
• Always confirm mechanical capture (pulse, BP) - not just ECG capture

Step 9: Extracorporeal Support

• ECMO (extracorporeal membrane oxygenation) or IABP for refractory cardiogenic shock
• Bridge to recovery - CCB toxicity is potentially reversible
• Consider early in severe cases unresponsive to pharmacotherapy
• Hemodialysis: NOT effective for CCBs (high protein binding, large volume of distribution)

5. DISPOSITION

Exam pearl: Extended-release formulations can cause delayed onset of toxicity up to 6-8 hours post-ingestion. Never discharge a sustained-release CCB ingestion without 24 hours of monitoring.

6. HIGH-YIELD EXAM SUMMARY TABLE

7. CLASSIC EXAM PITFALLS

1. "Atropine failed, now what?" - Move to calcium + HDI immediately. Atropine usually fails in significant CCB overdose.
2. "Patient took SR verapamil 2 hours ago, looks fine" - Admit for 24 hours. Delayed toxicity is the rule with extended-release formulations.
3. "Hyperglycemia in a non-diabetic after suspected overdose" - Think CCB toxicity (blocked pancreatic beta-cell insulin release).
4. "Pacing shows capture on ECG but no pulse" - Electrical-only capture; CCB toxicity impairs mechanical contraction. Add HDI/calcium.
5. "Calcium chloride vs. gluconate" - CaCl has 3x more elemental calcium; use it for severe/refractory cases (but avoid extravasation - caustic to tissue with peripheral IV).
6. "Co-ingestion with beta-blocker" - Treat as catastrophic synergy; escalate to HDI + vasopressors early.

• CCB class determines HR response: non-DHPs (verapamil/diltiazem) = bradycardia; DHPs ("pines") = reflex tachycardia
• Hyperglycemia is a toxicity marker (blocked pancreatic beta-cell insulin)
• Treatment ladder: Atropine (often fails) → Calcium → HDI (1 unit/kg bolus, up to 10 units/kg/hr) → Vasopressors (MAP goal ≥65) → Glucagon → Lipid emulsion → ECMO
• HDI protocol numbers are frequently tested: bolus 1 unit/kg, infusion 1-10 units/kg/hr, glucose check every 15-20 min
• SR formulations = mandatory 24-hour admission regardless of initial appearance